Immuno-Oncology Diagnostics Market Forecasts by Assay Type, Technology and Customer with Executive and Consultant Guides 2023 to 2027
“Explosion in immuno-oncology therapies creates an explosive diagnostic market. Diagnostics play a new key role in therapeutic development and clinical trials….”
Publication date: January 11, 2023
Page count: 441
Diagnostics and companion diagnostics are driving the success of Immuno-oncology therapeutics. An entire new segment of the diagnostics industry is being created which promises to grow dramatically; histology, genomics and liquid biopsy are converging. A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer. The approach seems to be working and showing great promise.
This is a complex field and this readable report will bring company management teams up to speed on both the technology and the opportunity.
The report provides detailed forecasting to 2027 by the following:
- Assay Type
- Checkpoint, Cytokine, Germline Genetic, Genetic Tumor, Tumor Microenvironment, Other
- NGS, PCR, FISH/IHC, Chem/IA
- Pharma, Clinic, Other Genetic
Understand growth expectations and the ultimate potential market size.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options, however your order is available as a credit if you wish to upgrade. We wrote this report and are ready by phone or email to help you use it.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School